SCHEMBL365560

SCHEMBL365560

COc1ccc(Cn2cc3c(n2)CC(OC(=O)N(C)C)CCC3=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
CHRM1 P11229 4/20 0.38
CHRM3 P20309 4/20 0.38
CHRM5 P08912 3/20 0.38
CACNA1G O43497 3/20 0.36
CACNA1H O95180 3/20 0.36
CACNA1I Q9P0X4 3/20 0.36
CHRM2 P08172 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365744 0.86 AADAT (0.47) AADATSMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL365671 0.83 AADAT (0.43) AADATSMN1; SMN2ALDH1A1CHRM1CHRM3
SCHEMBL366071 0.82 AADAT (0.50) AADATSMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL7670133 0.80 AADAT (0.47) AADATSMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL15277580 0.77 ELANE (0.34) CHRM1CHRM3CHRM5MEN1KMT2A
SCHEMBL6837301 0.76 ALDH1A1 (0.48) AADATSMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL365659 0.76 ALDH1A1 (0.48) AADATSMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL29191592 0.75 AADAT (0.51) AADATSMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL29191609 0.75 AADAT (0.51) AADATSMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL15182504 0.73 AADAT (0.46) AADATMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885SMN1; SMN2 2061/4885ALDH1A1 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.